

Daring Greatly in the Field

Carri Glide-Hurst, Ph.D., DABR

Director of Translational Research, Radiation Oncology, Henry Ford Health System
Associate Professor FTA, Wayne State University

all for you



FAILING* Greatly in the Field *because if you aren't failing, you aren't daring

Carri Glide-Hurst, Ph.D., DABR

Director of Translational Research, Radiation Oncology, Henry Ford Health System
Associate Professor FTA, Wayne State University

all for you



Disclosures

- Research funding provided by:
 - NIH R01CA204189
 - Philips Healthcare
 - HFHS A-Grant
- Research Collaborations with Modus Medical Devices, ViewRay, Inc, MedSpira

all for you



Failing Greatly Story #1 2014 in Detroit, Michigan, playing with Legos



STRING/PULLEY SYSTEM

“Well if you can bring someone like James Balter along with you, I would be more open to it.”

all for you




My Reaction



all for you




Found a new partnership: Modus Medical



all for you




Found a new partnership: Modus Medical



HENRY FORD
CANCER INSTITUTE

Partnered on my RoI, Invented PETE

- MR-compatible phantom simulated changes in rectum volumes (Empty, medium, full)
- Imaged using clinical protocol and performed ART workflow
- Generated various ART plans, evaluated 2ndary calculation, conducted PSQA on ART plan (film & point dose)



J. Cunningham et al., JACMP, 2018

IOPscience
 Implementing MRI & MR-SIM for Radiation Oncology: What You Need to Know by Dr. Glide-Hurst
 "QA in the era of MR-SIM and MRgRT"
 Don't miss this 30 minute talk by Dr. Curt Glide-Hurst
 Monday, Nov. 26th at 12:30PM
 #IOP2019 #IOP2019 #IOP2019
 Register Now

Failing Greatly Story #2

1st (2013) and 2nd (2015) NIH Ro1 grants I submitted: Both "Not Discussed"

- Several key areas were missing:
 - My publication record was not in the area that I was proposing
 - I was seen as too junior for the proposed work
- The PI seems to have no publication record on MRI.
- While the list of collaborators is long (see above) and is a strength of the proposal, it seems that many of the co-investigators were listed for symbolic reasons to boost the PIs reputation for this
- The principle investigator has limited experience and has not led a project of this complexity before.

all for you HENRY FORD CANCER INSTITUTE

My least favorite comment of all time

- Although she means well, her comment suggests that while we have many collaborators to cover all areas, there is a doubt about her ability to handle the huge amount of data in the various imaging modalities.

all for you HENRY FORD CANCER INSTITUTE

After eating a gallon of chocolate ice cream in one sitting, I got to work...

I took 1.5 years off from grant writing to:

- Study grant writing, attend seminars (RSNA), watch webinars
- Build outside collaborations with others who would later become co-investigators
- Hire a talented Research Scientist (Weili Zheng, PhD) who was instrumental in my productivity and data analysis
- Produce manuscripts to prove my expertise in MRI: Published three 1st author, three co-author, & three senior author during this timeframe
- Submitted June 5, 2015 and importantly, continued working toward the specific aims

And then... Nov, 2015, I got a score!!


Principal Investigator: GLIDE-HURST, CARRI KAYE PHD
 Applicant Organization: HENRY FORD HEALTH SYSTEM
 Review Group: ZRG1 SBIB-D (57)
 Meeting Date: 10/15/2015
 Council: JAN 2016
 Requested Start: 04/01/2016
 Application Number: 1 R01 CA204189-01
 Center for Scientific Review Special Emphasis Panel
 PAR Panel: Academic Industrial Partnership
 RFA/PA: PAR15-075
 PCC: SPDI
 Dual IC(s): EB
 Project Title: Development of Anatomical Patient Models to Facilitate MR-only Treatment Planning
 SRG Action: Impact Score: 44 Percentile: 37 #
 Next Steps: [http://www.fda.gov/oc/ohrt/ohrt_steps.htm](#)
 Human Subjects: 30-Human subjects involved - Certified, no SRG concerns
 Animal Subjects: 10-No live vertebrate animals involved for competing appl.
 Gender: 1A-Both genders, scientifically acceptable
 Minority: 1A-Minorities and non-minorities, scientifically acceptable
 Children: 3A-No children included, scientifically acceptable
 Clinical Research - not NIH-defined Phase III Trial

The score came with a caveat...

If you choose to submit a resubmission application for the next review cycle under this policy for new investigators, your amended application must be received at NIH no later than Thursday, December 10, 2015.

<1 month!! To recover from a 37th percentile!!





Takehome Messages

- When someone says no, someone else may say yes
- That yes may lead to better things than you may have imagined
- Persistence pays off
- To dare greatly, don't be afraid to fail greatly
